VIGL: Vigil Neuroscience Price to Sales
Adherence to ESG standards obligates Vigil Neuroscience (VIGL) to minimize environmental impact through energy-saving measures in its laboratories. The current P/S ratio visualizes the market valuation of these expenditures, where reflects the latest value of the metric. Asset value here is driven by science rather than GDP, which guarantees macro-stability. This stability is further supported by a strong staff of neuroimmunologists and the targeted hiring of clinical research experts.
Metric breakdowns and analytics for Vigil Neuroscience (VIGL)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- business debt structure and liquidity details:
- company profitability and valuation multiples indicators:
VIGL - Company Net Income|Net Profit Forecast Vigil Neuroscience|VIGL - P/E Multiple|Projected Price to Earnings vigilneuro.com|VIGL - PEG Multiple|Company Value to EBITDA Vigil Neuro|VIGL - Operating profit before deduction of amortization|Earnings per share for the last twelve months Vigil Neuroscience|VIGL - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months vigilneuro.com|VIGL - Earnings growth in current year|Net earnings per one share growth forecast for next year Vigil Neuroscience
- total revenue and sales volume data:
General company analysis:VIGL (Vigil Neuroscience Inc.)
The market capitalization-to-revenue dynamics of Vigil Neuroscience (VIGL) reflect market expectations regarding the company's expansion into the immunological therapy segment for dementia and rare brain pathologies. This multiple is calculated by dividing the total business value by its annual turnover, allowing investors to assess the asset's degree of overvaluation and determine optimal entry points while accounting for capital stagnation risks.
Competing companies
biogen.com - Market Cap to Revenue Ratio|P/S Multiple NBIX (Neurocrine Biosciences, Inc.)|Regencell Bioscience Ltd (RGC) - Price to Sales|AXSM: Market Cap to Revenue|ACAD - P/S Multiple|Xenon Pharmaceuticals (XENE) - Price-to-Revenue Ratio|vikingtherapeutics.com - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Supernus|Price to Sales Catalyst Pharma CPRX|Price-to-Revenue Ratio Denali Therapeutics Inc (DNLI)|Price-to-Revenue Coefficient Harmony Corp|P/S Multiple BHVN (Biohaven Ltd.)|AMLX - Market Cap to Revenue|Trevi Therapeutics, Inc. - P/S Multiple|Price-to-Revenue Coefficient Praxis Precision Medicines Inc PRAX|AVXL: P/S Multiple|Price to Sales CeriBell EEG (CBLL)|Price-to-Revenue Ratio Prothena Biosciences|Market Cap to Revenue Ratio ALEC (Alector Therapeutics)|P/S Multiple ANNX|Market Cap to Revenue omeros.com OMER|P/S Multiple NGNE (Neurogene Corp)|AC Immune Inc (ACIU) - Price to Sales|VYGR: Market Cap to Revenue|NMRA: Price-to-Revenue Ratio|SCLX: P/S Multiple|TVGN - Price-to-Revenue Coefficient|ACOG (Alpha Cognition Inc) - P/S Multiple|CGTX - Price-to-Revenue Multiple|Price-to-Revenue Ratio Inhibikase Therapeutics (IKT)|Price-to-Revenue Ratio SAVA (cassavasciences.com)|Price-to-Revenue Ratio Assertio ASRT|COYA: Market Cap to Revenue Ratio|VistaGen Therapeutics Inc - P/S Multiple|Price to Sales Ovid Therapeutics Inc.|ABOS (Acumen Pharmaceuticals) - Market Cap to Revenue|cervomed.com (CRVO) - P/S Multiple|Price-to-Revenue Ratio Alterity Therapeutics Ltd.|CLNN: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio PepGen Inc. (PEPG)|JUNS - Price to Sales|Relmada Therapeutics - Market Cap to Revenue|annovisbio.com - Price-to-Revenue Ratio|Grace Tx - P/S Multiple|Price-to-Revenue Coefficient Firefly Neuroscience, Inc. AIFF|KLTO: P/S Multiple|Price-to-Revenue Multiple NeuroSense Therapeutics Ltd. NRSN|RVPH (Reviva Pharmaceuticals) - P/S Multiple|MetaVia, Inc. (MTVA) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio NeurAxis (NRXS)|Price-to-Revenue Ratio HSDT (heliusmedical.com)|Passage Bio - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio NEUP|NERV - Price-to-Revenue Ratio|ATHA (athira.com) - Market Cap to Revenue Ratio|ADXN: P/S Multiple|Price to Sales Alzamend Neuro (ALZN)|Market Cap to Revenue CYCN|P/S Multiple Protagenic|Price-to-Revenue Ratio Pasithea Therapeutics (KTTA)|CRGT (cortigent.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Avenue Therapeutics, Inc. ATXI|Brainstorm Cell Therapeutics Inc. (BCLI) - Price to Sales|CARA - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Chromocell CHRO|ELYM: P/S Multiple|Market Cap to Revenue Intra-Cellular Therapies, Inc.|LBPH (Longboard Pharmaceuticals, Inc.) - P/S Multiple|Marinus Pharmaceuticals Inc (MRNS) - Price-to-Revenue Coefficient|P/S Multiple NKGN|NRBO - Price to Sales|Price-to-Revenue Ratio Sage Therapeutics, Inc. SAGE|SNPX: Market Cap to Revenue Ratio|Trevena - P/S Multiple|anewmeds.com (WENA) - Market Cap to Revenue|CERE: P/S Multiple
